|
|
News Breaks | | | | November 26, 2012 | | 08:04 EDT |  | ALNY | Alnylam announces notice of allowance for new patents from USPTO
Alnylam Pharmaceuticals announced that the United States Patent and Trademark Office has issued Notices of Allowance for three patent applications from the company’s exclusively held Tuschl II patent estate. The USPTO has allowed claims in patent applications 12/537,602, 12/683,081 and 12/838,786 which cover compositions, methods, and uses of small interfering RNA that are important for the development and commercialization of RNAi therapeutics. These newly allowed claims are the first to emerge from the U.S. prosecution of the Tuschl II patent series that include composition of matter for siRNA, the molecules that mediate RNAi. | |
|
News For ALNY From The Last 14 Days Check below for free stories on ALNY the last two weeks. |
|
|
| May 17, 2013 | | 08:04 EDT | | ALNY | Alnylam announces proof-of-concept data from RNAi program
 Subscribe for More Information | | | May 16, 2013 | | 07:29 EDT |  | ALNY | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | | | May 14, 2013 | | 08:43 EDT |  | ALNY | Alnylam has multiple upcoming positive catalysts, says JMP Securities
JMP Securities believes that Alnylam will have multiple positive data catalysts over the next two months. The firm thinks that upcoming data and presentations will enhance the company's positioning and perception of its pipeline, and it keeps an Outperform rating on the shares. | | | May 6, 2013 | | 16:04 EDT | | ALNY | Alnylam sees ending 2013 with over $320M in cash, equivalents
Subscribe for More Information | | | 16:03 EDT |  | ALNY | Alnylam reports Q1 EPS (15c), consensus (29c)
Subscribe for More Information | |
|
|
|
|
|
|
